Endologix, Inc. (NASDAQ:ELGX) hit a new 52-week low during trading on Tuesday . The stock traded as low as $0.86 and last traded at $0.88, with a volume of 15261 shares changing hands. The stock had previously closed at $0.94.

Several brokerages have commented on ELGX. Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating and set a $1.50 target price for the company in a research note on Friday, November 2nd. BidaskClub downgraded shares of Endologix from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Oppenheimer set a $3.00 target price on shares of Endologix and gave the company a “hold” rating in a research note on Friday, November 2nd. BTIG Research reaffirmed a “buy” rating on shares of Endologix in a research note on Sunday, November 4th. Finally, Piper Jaffray Companies downgraded shares of Endologix from an “overweight” rating to a “neutral” rating in a research note on Friday, August 10th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.08.

The company has a current ratio of 1.55, a quick ratio of 0.96 and a debt-to-equity ratio of 4.38. The company has a market cap of $105.52 million, a P/E ratio of -1.77 and a beta of 0.43.

Endologix (NASDAQ:ELGX) last issued its earnings results on Thursday, November 1st. The medical instruments supplier reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.09. Endologix had a negative net margin of 41.19% and a negative return on equity of 89.31%. The firm had revenue of $34.76 million during the quarter, compared to the consensus estimate of $33.04 million. During the same quarter in the prior year, the firm earned ($0.17) earnings per share. The business’s quarterly revenue was down 24.4% on a year-over-year basis. As a group, equities analysts predict that Endologix, Inc. will post -0.74 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in shares of Endologix during the third quarter worth $116,000. Renaissance Technologies LLC bought a new stake in shares of Endologix during the third quarter worth $165,000. Paloma Partners Management Co bought a new stake in shares of Endologix during the third quarter worth $184,000. MetLife Investment Advisors LLC increased its position in shares of Endologix by 128.2% during the second quarter. MetLife Investment Advisors LLC now owns 41,313 shares of the medical instruments supplier’s stock worth $234,000 after acquiring an additional 23,210 shares in the last quarter. Finally, Engineers Gate Manager LP increased its position in shares of Endologix by 66.5% during the third quarter. Engineers Gate Manager LP now owns 129,959 shares of the medical instruments supplier’s stock worth $248,000 after acquiring an additional 51,886 shares in the last quarter. 75.51% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/11/20/endologix-elgx-hits-new-52-week-low-at-0-86.html.

About Endologix (NASDAQ:ELGX)

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Further Reading: Coverage Ratio

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.